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OBJECTIVE
In observational cohorts, adiponectin is inversely associated and free fatty acids
(FFAs) are directly associated with incident coronary heart disease (CHD). Adipo-
nectin tends to be reduced and FFAs elevated in type 2 diabetes. We investigated
relationships of adiponectin and FFA and major adverse cardiovascular events
(MACEs) and death in patients with acute coronary syndrome (ACS) and type 2 di-
abetes using data from the AleCardio (Effect of Aleglitazar on Cardiovascular
Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes
Mellitus) trial, which compared the PPAR-a/g agonist aleglitazar with placebo.
RESEARCH DESIGN AND METHODS
Using Cox regression adjusted for demographic, laboratory, and treatment var-
iables, we determined associations of baseline adiponectin and FFAs, or the change
in adiponectin and FFAs from baseline, with MACEs (cardiovascular death, myo-
cardial infarction, or stroke) and death.
RESULTS
A twofold higher baseline adiponectin (n = 6,998) was directly associated with risk
of MACEs (hazard ratio [HR] 1.17 [95% CI 1.08–1.27]) and death (HR 1.53 [95% CI
1.35–1.73]). A doubling of adiponectin from baseline to month 3 (n = 6,325) was also
associatedwith risk of death (HR 1.20 [95%CI 1.03–1.41]). Baseline FFAs (n = 7,038),
but not change in FFAs from baseline (n = 6,365), were directly associated with
greater risk ofMACEs and death. There were no interactions with study treatment.
CONCLUSIONS
In contrast toprior observational data for incidentCHD, adiponectin is prospectively
associated with MACEs and death in patients with type 2 diabetes and ACS, and an
increase in adiponectin from baseline is directly related to death. These ﬁndings
raise the possibility that adiponectin has different effects in patients with type 2
diabetes and ACS than in populations without prevalent cardiovascular disease.
Consistent with prior data, FFAs are directly associated with adverse outcomes.
Adiponectin and free fatty acids (FFAs) are markers of adipocyte function. Adiponectin
is a hormone secreted by adipocytes and signals through speciﬁc receptors in target
tissues, including myocardium and arterial wall. Adiponectin may modulate insulin
action and sensitivity and has putative antiatherogenic and anti-inﬂammatory ef-
fects (1). Infusion of adiponectin in experimental animals may mitigate myocardial
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ischemia-reperfusion injury (2). Obser-
vational analyses show a strong and
consistent association of higher adipo-
nectin levels with lower risk of incident
coronary heart disease (CHD) (3,4), but
Mendelian randomization analysis does
not support such an association (5). Stud-
ies in patients with established CHD
have also yielded conﬂicting evidence,
with some indicating favorable and
others adverse associations of adipo-
nectin with risk of future cardiovascu-
lar events (6–9). FFAs are an important
energy substrate; although at elevated
concentrations, FFAs may exert proin-
ﬂammatory, proapoptotic, or proarrhyth-
mic effects and impair endothelial function
(10–12).
Adipocyte dysfunction is a hallmark of
insulin-resistant states and is manifested
by reduced adiponectin and elevated FFA
levels. In fact, it has been postulated that
low adiponectin and high FFAs may con-
tribute to increased cardiovascular risk
in type 2 diabetes (3,13). Agonists of
the peroxisome proliferator–activated
receptor g (PPAR-g) are among the
most effective agents to raise adipo-
nectin and lower FFA concentrations in
circulation (14). The AleCardio (Effect
of Aleglitazar on Cardiovascular Out-
comes After Acute Coronary Syndrome
in Patients With Type 2 Diabetes Melli-
tus) trial compared the effects of the dual
PPAR-a/g agonist aleglitazar with pla-
cebo on cardiovascular morbidity and
mortality among patients with type 2
diabetes and acute coronary syndrome
(ACS) (NCT01042769, www.clinicaltrials
.gov). The AleCardio trial showed no
effect of aleglitazar on cardiovascular
outcomes. Using data from that trial,
we evaluated the association of adipo-
nectin and FFAs at baseline and on as-
signed study treatment with major
adverse cardiovascular events (MACEs)
and death.
RESEARCH DESIGN AND METHODS
Study Design and Patients
This study is a prespeciﬁed post hoc
analysis of the AleCardio trial data. Study
data and study materials are not publicly
available for other researchers, but an-
alytic methods can be requested from
the corresponding author. The ratio-
nale, design, and primary results of the
AleCardio trial have been published
previously (15,16). The protocol was
approved by institutional review boards,
and written informed consent was ob-
tained from all participants. At 720 par-
ticipating centers in 26 countries, 7,226
patients with established or newly di-
agnosed type 2 diabetes and recent ACS
were randomly assigned to treatment
with aleglitazar 150 mg daily or placebo,
added to standard of care. Randomiza-
tion occurred during the interval span-
ning hospital discharge to 12 weeks after
the index ACS event. The primary out-
come measure was time to ﬁrst occur-
rence of cardiovascular death, nonfatal
myocardial infarction (MI), or nonfatal
stroke (deﬁned as MACEs for this anal-
ysis). All-cause and cardiovascular deaths
were secondary efﬁcacy measures. Af-
ter a median follow-up of 2 years, the
trial was ended prematurely due to fu-
tility for efﬁcacy and in response to a
higher incidence of safety end points in
the aleglitazar group.
Laboratory Assessments
All laboratory analyses were conducted
by a central laboratory. Blood samples
were collected after an overnight fast of
at least 8 h at randomization and af-
ter 3 months of assigned study treat-
ment. Plasma adiponectinwasmeasured
by a quantitative sandwich ELISA (Quan-
tikine Adiponectin/Acrp30 Immunoas-
say; R&D Systems, Minneapolis, MN)
with an intra-assay coefﬁcient of vari-
ation of 2.5–4.7% and an interassay co-
efﬁcient of variation of 5.8–6.9%. FFAs
were measured by enzymatic colorime-
try (NEFA HR2; Wako Chemicals, Rich-
mond, VA)with an intra-assay coefﬁcient
of variation of 0.61–0.75% and an inter-
assay coefﬁcient of variation of 0.03–
0.37%. Results were reported with a
precision of 0.1 mmol/L. Testing was
performed on Roche Modular Analyzers.
Statistical Methods
We compared baseline characteristics
among quartiles of adiponectin and
four categories of FFA concentrations
using ANOVA or Kruskal-Wallis test for
continuous variables, depending on the
distribution, and x2 for categorical var-
iables. Categories of FFAs were used
instead of exact quartiles because the
precision of measurement of FFA con-
centrations was 0.1 mmol/L, resulting in
an unequal distribution of participants
across quartiles. The distributions of
adiponectin and FFA concentrations
were checked, and log transformation
was conducted if required for further
analysis.
Correlation between two variables
was speciﬁed by the Pearson or Spear-
man correlation coefﬁcient, as appropri-
ate. Cox proportional hazards regression
models were used to analyze the asso-
ciation between baseline adiponectin or
FFA levels and time to event for MACE,
all-cause death, and cardiovascular
death. Additionally, we modeled the as-
sociation between change in adiponec-
tin or change in FFAs from baseline to
month 3 of assigned study treatment
with each of the three end points (oc-
curring after month 3). We adjusted all
models for covariates and treatment, and
we stratiﬁed for the type of index ACS
event (unstable angina, non–ST segment
elevation MI, or ST segment elevation
MI) and the need for reperfusion ther-
apy for the index ACS event. We checked
for a potential interaction with treatment
and sex and stratiﬁed if necessary. The
proportional hazards assumption and
functional form of the covariates were
evaluated using the ASSESS statement
in SAS. Visual inspection of the cumula-
tive Martingale residuals and the formal
hypothesis based on simulation were
assessed.
We included the following covariates
in our model: age; sex; race; geographi-
cal region; prior history of MI, stroke or
transient ischemic attack, heart failure,
and hypertension; duration of diabetes;
smoking history; BMI; time from ACS
to randomization; systolic and diastolic
bloodpressure; useof antihyperglycemic
agents (insulin, sulfonylureas, and bigua-
nides); HbA1c; fasting plasma glucose;
LDL cholesterol; HDL cholesterol; triglyc-
erides; hs-CRP; and estimated glomer-
ular ﬁltration rate (eGFR). Adiponectin or
FFA concentration was added as a co-
variate, depending upon which of those
was the variable of interest in the anal-
ysis. All covariates were selected a priori
based on their relation with adiponectin,
FFAs, or cardiovascular outcomes, as de-
scribed in prior literature.
In the analysis on change in adiponec-
tin or FFAs from baseline to month 3,
additional adjustment was performed
for concurrent changes in systolic and
diastolic blood pressure, glucose, insulin,
HbA1c, LDL cholesterol, HDL cholesterol,
triglycerides, eGFR, adiponectin (for
analysis on change in FFAs), and FFAs
(for analysis on change in adiponectin).
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Two sensitivity analyses were per-
formed. In the ﬁrst, patients treated
with exogenous insulin were excluded. In
the second, N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) was added
as a covariate to the multivariable model
because prior studies showed that NT-
proBNP may be related to adiponectin
concentrations (17,18).
Missing covariate data were replaced
with use of multiple imputation (Markov
chain Monte Carlo method). Results
were considered signiﬁcantly different
at a P value of,0.05. Statistical analyses
were performed using SAS statistical
software version 9.2 (SAS Institute, Cary,
NC).
RESULTS
Baseline Characteristics
Baseline adiponectin and FFAs were
available for 6,998 and 7,038 patients,
respectively. The distribution of base-
line levels is tabulated in Supplementary
Table 1 and illustrated in Supplemen-
tary Fig. 1. Adiponectin and FFA values
both have a skewed distribution. The
median (interquartile range [IQR]) of
adiponectin was 4.0 mg/mL (2.7–6.1).
The four categories of FFAs were 0.1–
0.3 mmol/L (n = 1,878), 0.4–0.5 mmol/L
(n = 2,308), 0.6–0.7 mmol/L (n = 1,683),
and 0.8–3.3 mmol/L (n = 1,169). As
expected, baseline adiponectin and
FFA concentrations did not differ be-
tween the aleglitazar and placebo
groups. Paired baseline and month 3
measurements of adiponectin and FFAs
were available for 6,325 and 6,365
patients, respectively. Tables 1 and
2 show baseline characteristics strati-
ﬁed according to adiponectin quartiles
and FFA categories. Patients with higher
adiponectin levels were older, more fre-
quently women, and had a longer dura-
tion of type 2 diabetes. They had lower
insulin, triglyceride, and eGFR but higher
NT-proBNP, HDL cholesterol, and LDL
cholesterol levels. Further, they were
more likely to be treated with exogenous
insulin but less likely to be treated with
biguanides and diuretics.
Differences in baseline characteristics
stratiﬁed according to FFA categories
were less pronounced than those ob-
served across quartiles of adiponectin.
Nonetheless, patients with higher FFA
levels were older, more frequently women,
less frequently past/current smokers,
and had a longer duration of type 2
diabetes. They had lower insulin, higher
adiponectin, and higher NT-proBNP levels
compared with patients with lower FFA
levels.
In the aleglitazar arm, median (IQR)
adiponectin concentration increased
from baseline (4.0 mg/mL [2.7–6.1]) to
month 3 (11.9 mg/mL [7.1–19.4]), an
increase of 7.5 mg/mL (3.7–13.7) (P ,
0.001). In the placebo group, adiponectin
at month 3 was 4.1 mg/mL (2.6–6.0), a
change of 0.0 mg/mL (20.9 to 0.9) from
baseline (Supplementary Table 1 and
Supplementary Figs. 2 and 3). FFAs de-
creased from 0.56 0.3 mmol/L at base-
line to 0.4 6 0.2 mmol/L at month 3 in
the aleglitazar arm (a decrease of20.16
0.3 mmol/L, P, 0.001). In the placebo
group, FFAs at month 3 was 0.5 6
0.3 mmol/L, a change of 0.0 6 0.3
mmol/L from baseline.
Association Between Baseline
Adiponectin and FFA Levels and
Outcomes
A total of 684 (10%) and 688 (10%)
MACEs, 276 (4%) and 281 (4%) all-cause
deaths, and 202 (3%) and 206 (3%) car-
diovascular deaths occurred in patients
with baseline adiponectin and FFA data
available, respectively. Median (IQR)
follow-up time was 1.98 years (1.55–
2.46). Figure 1 shows the Kaplan-Meier
estimates of survival free of MACEs, all-
cause death, and cardiovascular death
according to adiponectin quartiles and
FFA categories. The risk for each end
point increased across quartiles of adipo-
nectin (P , 0.001) and categories of FFAs
(P , 0.05).
Table 3 shows the crude and adjusted
risk for MACEs, all-cause death, and car-
diovascular death according to base-
line adiponectin and FFA concentrations.
Baseline adiponectin that was two times
higher was associated with higher risk
for MACEs (hazard ratio [HR] 1.28 [95%
CI 1.18–1.38], adjusted HR 1.17 [1.08–
1.27]; P , 0.001), all-cause death (HR
1.75 [1.56–1.98], adjusted HR 1.53 [1.35–
1.73]; P , 0.001), and cardiovascular
death (HR 1.67 [1.45–1.92], adjusted
HR 1.51 [1.30–1.76]; P , 0.001). No in-
teraction existed between randomized
treatment assignment and baseline adi-
ponectin concentrations and the risk for
any end point event (Table 3). Further-
more, no interaction was found for sex.
A baseline FFA level that was two times
higher was associated with a higher risk
forMACEs (HR1.15 [1.04–1.27], adjusted
HR 1.12 [1.02–1.24]; P = 0.019), all-cause
death (HR 1.31 [1.11–1.54], adjusted HR
1.20 [1.03–1.40]; P = 0.018), and cardio-
vascular death (HR 1.28 [1.06–1.54],
adjusted HR 1.19 [0.99–1.42]; P =
0.062). As with adiponectin, the interac-
tion between treatment and baseline
FFA concentrations and end point events
was not signiﬁcant.
In the ﬁrst sensitivity analysis, patients
treated with exogenous insulin were
excluded. The associations of baseline
adiponectin with clinical outcomes re-
mained signiﬁcant with minimal effect
on the point estimates of HRs (data not
shown); however, the association of
baseline FFAs with adverse outcomes
was no longer signiﬁcant. Adiponectin
and NT-proBNP were weakly correlated
with r2 = 0.09 (P, 0.001). In the second
sensitivity analysis with NT-proBNP
added as a covariate to the regression
model, a baseline adiponectin level that
was two times higher remained signiﬁ-
cantly associated with MACEs (adjusted
HR 1.14 [1.04–1.26], P = 0.008), all-cause
death (adjusted HR 1.19 [1.02–1.39], P =
0.025), and cardiovascular death (ad-
justed HR 1.21 [1.01–1.44], P = 0.040),
although the associations were attenu-
ated (Table 3). With the addition of
NT-proBNP as a covariate, the associa-
tions of baseline FFAs with death and
cardiovascular death remained signiﬁ-
cant, but the association with MACEs
was attenuated. A similar effect was
seen for the separate end-point nonfatal
MI (Supplementary Table 2).
Association Between Change in
Adiponectin or FFAs and Outcomes
The associations between changes in
adiponectin or FFAs from baseline to
month 3 and outcomes are shown in
Table 3. A doubling in adiponectin from
baseline to month 3 was associated
with a higher risk for all-cause death
(HR 1.20 [1.03–1.41], P = 0.022) and
cardiovascular death (HR 1.22 [1.02–
1.46], P = 0.029) but not MACEs (HR
1.03 [0.93–1.15], P = 0.540) after multi-
variable adjustment. Because a change in
adiponectin over time was identiﬁed only
in the aleglitazar group (Supplementary
Table 1, P , 0.001), we investigated
interaction effects by treatment and
conducted stratiﬁed analysis by treat-
ment. No signiﬁcant interaction effects
were observed. In addition, interaction
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with sex was investigated and no inter-
action was found, with the exception for
the association between change in adi-
ponectin and MACEs (P = 0.031). Strat-
iﬁed analysis showed no association
between change in adiponectin and
MACEs in men (HR 0.99 [0.87–1.12], P =
0.82), whereas a borderline signiﬁcant
association for women existed (HR 1.19
[1.00–1.42], P = 0.052). The change in
FFAs from baseline to month 3 was not
associated with outcomes in crude or
adjusted models.
When sensitivity analysis was per-
formed by adding NT-proBNP as cova-
riate to the model, associations between
change in adiponectin (baseline tomonth
3) and outcomes were no longer signif-
icant (Table 3).
CONCLUSIONS
This study shows that both FFA and
adiponectin levels are directly associated
with the risk of MACEs and death in
patients with type 2 diabetes and recent
ACS. These ﬁndings extend the previ-
ously reported data on the relation be-
tween FFA levels and cardiovascular
outcomes; although the observed rela-
tionships for adiponectin are opposite
to conclusions from prior observational
data in patients initially free of cardio-
vascular events.
In prior cohort studies without prev-
alent cardiovascular disease, higher adi-
ponectin concentrations were related
to a lower risk of incident cardiovascular
disease and mortality (3,4). However, the
current data are aligned with ﬁndings
in patients with heart failure (19) or cor-
onary artery disease (20), and in elderly
people (21,22), that associated higher
concentrations of adiponectin with
greater risk of cardiovascular and all-
cause death. Furthermore, an analysis
of the Examination of Cardiovascular
Outcomes with Alogliptin versus Stan-
dard of Care in Patients With Type 2
Diabetes Mellitus and Acute Coronary
Syndrome (EXAMINE) trial showed a pos-
itive association of adiponectin with car-
diovascular and all-cause death (23). A
post hoc analysis of the Pravastatin or
Atorvastatin Evaluation and Infection
Therapy (PROVE IT) trial showed an
adverse association of adiponectin with
2-year MACE outcomes but not death
in 3,933 patients with recent ACS (24).
Additionally, in patients without dia-
betes and a recent acute MI, higher
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adiponectin levels have been associ-
ated with higher mortality but not car-
diovascular mortality (25). The current
data extend these ﬁndings by demon-
strating associations between baseline
adiponectin and death, as well as com-
positeMACEoutcomes. Furthermore, the
current analysis indicates that a rise in
adiponectin during the early period after
ACS is associated with a greater risk of
death, independent of treatment assign-
ment in the clinical trial that provided
the source data.
The underlying mechanisms for the
adverse associations of adiponectin and
FFAs with death and MACEs are unclear.
Although most evidence supports the view
of adiponectin as an anti-inﬂammatory
mediator (26), a growing body of in vitro
data indicates that adiponectin also
has the potential to induce proinﬂam-
matory effects. Studies in a variety of
cell types, including astrocytes (27),
renal tubular cells (28), synovial cells
(29), macrophages, and T cells (30),
demonstrate stimulation of inﬂamma-
tory signaling pathways by adiponectin.
In clinical studies of patients with in-
ﬂammatory or vascular disease, higher
adiponectin levels correlated with greater
severity of rheumatoid arthritis (31),
higher likelihood of proliferative dia-
betic retinopathy (32), and greater aortic
stiffness in patients with acute MI (33).
Alternatively, higher circulating con-
centrations of adiponectin may reﬂect
“adiponectin resistance” due to a de-
crease in adiponectin receptor expres-
sion or responsiveness in target tissues
(34). Under this concept, an adverse as-
sociation of adiponectin with outcomes
might not reﬂect adverse actions of the
adipokine but rather conditions that im-
pair signaling of its favorable effects.
Prior studies have shown a consistent
positive association between the circu-
lating concentrations of adiponectin
and natriuretic peptides (17,19,35), with
evidence that natriuretic peptides stim-
ulate the synthesis and release of adi-
ponectin (18,36). Natriuretic peptides
are increased in heart failure and predict
poor outcomes. Therefore, we investi-
gated the possibility that the adverse
association of adiponectin with outcomes
after ACS reﬂect an underlying adverse
association of heart failure and elevated
natriuretic peptides. In sensitivity analy-
ses incorporating levels of NT-proBNP as
a covariate in Cox regression models,
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signiﬁcant adverse associations per-
sisted between baseline adiponectin and
death and MACE outcomes, although
the HRs were somewhat attenuated.
Thus, higher levels of natriuretic peptides
may explain part, but not all, of the par-
adoxical association of adiponectin with
adverse outcomes in this study.
Elevated FFA levels in our study pop-
ulation are comparable to levels seen in
obese patients and patients with type 2
diabetes (37,38). Elevated FFAs have
been postulated to be a risk factor for
arrhythmic and atherothrombotic events
(9). In prior studies, higher FFA concen-
trations have been associated with
greater risk of incident CHD (39), MACEs
in patients with CHD (40), and sudden
death (41). The current study extends
those ﬁndings by demonstrating a strong
association of FFAs with MACEs and
death in patients with type 2 diabetes
and ACS.
Study Limitations
The current study is a post hoc obser-
vational analysis of a randomized clinical
trial. As such, it cannot determine the
biological mechanisms responsible for
the adverse association of adiponec-
tin or FFAs with outcomes. Second,
unaccounted factors associated with
adiponectin or FFAs may introduce an un-
known degree of residual confounding.
For example, we did not measure and
therefore cannot account for relation-
ships with other adipokines (e.g., leptin
and ghrelin). Third, because of missing
data in baseline or change in adiponectin
and FFA concentrations, we had to ex-
clude;3% and 12% of the patients from
our analyses, respectively. Fourth, anal-
yses relating the change in adiponectin or
FFAs from baseline to month 3 to out-
comes have substantially less power than
those relating baseline concentrations
to outcomes. This is because there were
fewer patients with data from both time
points and because the analyses of the
changes in biomarkers over time only
consider events occurring after month 3.
Moreover, the median change in FFAs
from baseline was modest, further re-
ducing power in that analysis. Fifth, the
relationship of adiponectin and FFA con-
centrations with the qualifying (index)
ACS event for the AleCardio study is
unknown. Therefore, we cannot exclude
index event bias as an explanation for the
current ﬁndings (42). Sixth, adiponectin
and FFAs were measured only once at
each time point. Intraindividual variabil-
ity in these measures may have weak-
ened the apparent associations with
outcomes. By analogy, intraindividual
variability in NT-proBNP may have weak-
ened the effects of adjustment for that
variable. Furthermore, a total of 452 pa-
tients in AleCardio either withdrew con-
sent or were lost to follow-up prior to
the common study end date. We cannot
exclude the possibility of resulting bias
in our reported results. Finally, the re-
ported adiponectin concentrations rep-
resent total adiponectin levels, without
discriminating between the low- and
more metabolically active high-molecular-
weight fractions. However, Kizer et al.
(43) found a similar direct positive re-
lation for total and high-molecular-
weight adiponectin with cardiovascular
and all-cause mortality in older people
from the Cardiovascular Health Study.
Conclusion
Inpatientswith type2diabetesandrecent
ACS, both baseline adiponectin and FFA
Figure 1—Kaplan-Meier curves of survival free of MACEs, all-cause death, and cardiovascular death by baseline adiponectin quartiles (A) and FFA
categories (B) with 95% CI bands.
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levels are directly associated with the risk
of MACEs and death. These relationships
persist after multivariable adjustment.
Additional adjustment for NT-proBNP at-
tenuates, but does not abrogate, these
associations. Moreover, an increase in
adiponectin during the 3 months after
the ACS event is associated with higher
risk for all-cause and cardiovascular death
after multivariable adjustment. The neutral
results of the AleCardio trial may reﬂect
a balance between beneﬁcial and adverse
effects of aleglitazar. Beneﬁcial effectsmay
include reduced FFAs, as well as reduced
glycemic indices and triglycerides and in-
creased HDL cholesterol. Adverse effects
of aleglitazar may include increased adipo-
nectin, as well as increased LDL choles-
terol and creatinine levels, as previously
described (16). The present results sug-
gest that interventions that are speciﬁcally
intended to increase adiponectin are un-
likely to be useful in patients with CHD.
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Table 3—HRs and point estimates of end points per doubling of adiponectin and FFA concentrations at baseline and from
baseline to month 3
Crude model
Multivariable
model
Interaction of
treatment
assignment
Multivariable
model +
NT-proBNP
n Events (%) HR (95% CI) HR (95% CI)
Point estimate
(95% CI)* HR (95% CI)
Baseline adiponectin MACEs 6,998 684 (10%) 1.28 (1.18–1.38)† 1.17 (1.08–1.27)† 1.12 (0.96–1.31) 1.14 (1.04–1.26)†
All-cause
death
6,998 276 (4%) 1.75 (1.56–1.98)† 1.53 (1.35–1.73)† 1.07 (0.85–1.36) 1.19 (1.02–1.39)‡
CV death 6,998 202 (3%) 1.67 (1.45–1.92)† 1.51 (1.30–1.76)† 1.02 (0.77–1.35) 1.21 (1.01–1.44)‡
Baseline FFAs MACEs 7,038 688 (10%) 1.15 (1.04–1.27)† 1.12 (1.02–1.24)‡ 0.94 (0.78–1.14) 1.02 (0.93–1.11)
All-cause
death
7,038 281 (4%) 1.31 (1.11–1.54)† 1.20 (1.03–1.40)‡ 1.07 (0.79–1.44) 1.22 (1.07–1.40)†
CV death 7,038 206 (3%) 1.28 (1.06–1.54)‡ 1.19 (0.99–1.42) 1.05 (0.74–1.51) 1.14 (0.97–1.33)
Change in adiponectin MACEs 6,212 443 (7%) 0.92 (0.84–1.01) 1.03 (0.93–1.15) 0.95 (0.73–1.25) 1.00 (0.90–1.10)
All-cause
death
6,325 188 (3%) 1.00 (0.87–1.14) 1.20 (1.03–1.41)‡ 0.84 (0.56–1.28) 1.06 (0.90–1.24)
CV death 6,325 130 (2%) 1.03 (0.87–1.21) 1.22 (1.02–1.46)‡ 0.91 (0.55–1.49) 1.06 (0.89–1.26)
Change in FFAs MACEs 6,253 448 (7%) 0.96 (0.87–1.06) 0.92 (0.84–1.02) 1.12 (0.92–1.36) 0.93 (0.85–1.03)
All-cause
death
6,365 191 (3%) 0.88 (0.73–1.06) 0.93 (0.80–1.08) 1.01 (0.75–1.35) 0.93 (0.80–1.08)
CV death 6,365 131 (2%) 0.90 (0.77–1.04) 0.90 (0.75–1.08) 1.12 (0.79–1.59) 0.89 (0.74–1.07)
The multivariable model was adjusted for treatment; baseline log2(FFA) or log2(adiponectin); age; sex; race; region; prior history of MI, stroke or
transient ischemic attack, heart failure, and hypertension; duration of diabetes; smoking history; BMI; time from ACS to randomization; systolic and
diastolic blood pressure; use of antihyperglycemic agents (insulin, sulfonylureas, biguanides); HbA1c; fasting plasma glucose; LDL; HDL; triglycerides;
hs-CRP; and eGFR. The model was stratiﬁed by ACS index event and reperfusion therapy for ACS. The multivariable model + NT-proBNP was
the multivariable model with additional adjustment for log (NT-proBNP). Change models were additionally adjusted for change in log2(FFA)
or log2(adiponectin) and change in systolic and diastolic blood pressure, HbA1c, fasting plasma glucose, LDL, HDL, triglycerides, hs-CRP, and eGFR
from baseline to month 3. The interaction model was the multivariable model with extra adjustment for interaction with treatment. CV,
cardiovascular. *Pointestimateshown is the ratiobywhich theHRof themultivariablemodel changeswhengoing fromaleglitazar toplacebo.†P,0.01.
‡P , 0.05.
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integrity of the data and the accuracy of the data
analysis.
Prior Presentation. This study was presented
at the 2016 Scientiﬁc Sessions of the Ameri-
can Heart Association, New Orleans, LA, 12–16
November 2016.
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